HC Wainwright Raises Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $50.00

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective hoisted by HC Wainwright from $47.00 to $50.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

Several other brokerages have also issued reports on COLL. Truist Financial increased their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a buy rating in a research note on Friday, August 9th. Piper Sandler reissued a neutral rating and set a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Needham & Company LLC reaffirmed a hold rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a hold rating to a buy rating and increased their price target for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Finally, StockNews.com cut Collegium Pharmaceutical from a strong-buy rating to a buy rating in a research note on Saturday, August 31st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $42.60.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock opened at $37.19 on Thursday. The company has a market cap of $1.22 billion, a P/E ratio of 15.50 and a beta of 0.94. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. The business has a 50-day moving average price of $35.01 and a two-hundred day moving average price of $35.35. Collegium Pharmaceutical has a 1-year low of $20.95 and a 1-year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The business had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.13 earnings per share. As a group, analysts anticipate that Collegium Pharmaceutical will post 5.89 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at $4,602,166.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Gladius Capital Management LP purchased a new position in Collegium Pharmaceutical in the second quarter worth $32,000. Principal Securities Inc. bought a new position in Collegium Pharmaceutical during the fourth quarter valued at about $40,000. nVerses Capital LLC increased its holdings in Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the last quarter. Assetmark Inc. raised its position in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 1,108 shares during the period. Finally, Sheaff Brock Investment Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the 1st quarter valued at approximately $204,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.